Genmab Profit Drops In Q3, Maintains FY26 Revenue Outlook
Genmab reported Q3 net profit of $342M, down from $401M YoY, with revenue rising to $1.187B. Nine-month revenue reached $3.238B, up from $2.662B. The company maintained its 2026 revenue outlook of $4.33B-$4.53B. GMAB shares fell 2.23% to $53.89.
How this was made
The 30-second read
Why it matters
The Q3 earnings miss may trigger short‑term sell pressure, but the unchanged FY26 revenue guidance could support a rebound if subsequent quarters deliver stronger royalties.
Market read
First‑time earnings release with lower profit and a modest share decline; traders may adjust positions in GMAB and related biotech stocks.
What to watch
Higher royalty and collaboration revenue could offset profit weakness in later quarters.
Background
Genmab A/S is a Danish biotech listed on Nasdaq under the ticker GMAB, known for antibody‑drug conjugates.
Ticker impact
Genmab reported Q3 net profit of $342M, down from $401M YoY, and its shares fell 2.23% on Nasdaq.
likely pressure as the market prices in the profit drop and slower growth
The earnings miss and share price decline indicate investors may sell on weaker profitability.
Market effects
Biotech sector may see modest pullback as a mid‑cap earnings miss highlights profit pressure.
European biotech firms could face heightened scrutiny on margins.
Limited; impact confined to Genmab and peers monitoring earnings quality.
Counterpoint
Despite the profit drop, FY26 revenue outlook remains unchanged, suggesting upside if guidance holds.
Key entities
- companyGenmab A/S
Danish biotech firm developing antibody‑drug conjugates.
